NuCana
Update in progressNCNA (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
NuCana plc is a clinical-stage biopharma focused on transforming chemotherapy and nucleoside analogs with its ProTide technology to improve cancer medicines. Its pipeline features NUC-3373, based on 5-fluorouracil, in Phase 1b/2 for metastatic colorectal cancer and other solid tumors, and NUC-7738 in Phase 2 of a 1/2 trial for advanced solid tumors. It collaborates with Cardiff ProTides and is based in Edinburgh, formed in 1997.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited Kingdom
- CEOMr. Hugh Stephen Griffith
- Founded1997
- Employees10
- Websitewww.nucana.com
Identifiers
- ISINUS67022C2052
- FIGIBBG00HMJNMV8
- CUSIP67022C106
- CIK0001709626